CD276 and neuroblastoma: Recent studies have shown that MYCN‐amplified NB tumors express lower levels of miR‐29a that directly target an immune checkpoint member B7‐H3 (CD276) and facilitate neoplastic neuroblast cells to escape the immune surveillance (Espinosa‐Parrilla et al., 2014; Xu et al., 2009).